Skip to main content

CEA - Carcinoembryonic Antigen

How is it used?
CEA is most useful to monitor treatment of cancer patients. It is used with patients who have had surgery to measure response to therapy and to monitor whether the disease is recurring. A blood test for CEA is often used as a tumor marker. Physicians can use CEA results to determine the stage and extent of disease and the outlook in patients with cancer, especially gastrointestinal (GI) and, in particular, colorectal cancer.

CEA is also used as a marker for other forms of cancer. It has been found helpful in monitoring patients with cancer of the rectum, lung, breast, liver, pancreas, stomach, and ovary. Not all cancers produce CEA; therefore, the CEA test is not used for screening the general population.
[Back to top]

When is it ordered?

A CEA test is ordered when the patient’s symptoms suggest the possibility of cancer. The CEA level is also tested before treatment in cancer patients, especially patients with GI cancers. CEA levels are monitored during therapy. It is also used to follow up patients after therapy.
[Back to top]

What does the test result mean?

NOTE: A standard reference range is not available for this test. Because reference values are dependent on many factors, including patient age, gender, sample population, and test method, numeric test results have different meanings in different labs. Your lab report should include the specific reference range for your test. Lab Tests Online strongly recommends that you discuss your test results with your doctor. For more information on reference ranges, please read Reference Ranges and What They Mean.

On initial testing, patients with smaller and early-stage tumors are likely to have low, if not normal, CEA levels, while patients with more advanced tumors, or tumors that have spread throughout the body, are likely to have initially high CEA levels. When CEA levels decrease to “normal” levels after therapy, it means that the CEA-producing tumor has been removed. A steadily rising CEA level is occasionally the first sign of tumor recurrence.

[Back to top]

Comments

ivy.razmus said…
I found this link for HNPCC that has more information about somatic mutations and is not limited to HNPCC but also the breast cancer gene. http://www.matchtrace.com/links/somatic-mutation.htm

Popular posts from this blog

Cancer Survivors

Just read a story about one woman's cancer experience. I bet everyone has a story about what goes through your mind when you are told you have cancer. Her thought were about her stunned family members, one crying and the other in shock. I bet there are quite a few stories that could be qualitatively studied. Those experiences could help nurses better help patients during this time.

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer

Key Points Question    What is the frequency and spectrum of cancer susceptibility gene mutations among patients with colorectal cancer diagnosed at younger than 50 years? Findings    In this cohort study of 450 patients with early-onset colorectal cancer, 72 (16%) had a pathogenic mutation. Panel testing identified mutations in patients that may have otherwise been missed; specifically, 24 of 72 patients (33.3%) who were mutation positive did not meet testing criteria for the gene(s) in which they had a mutation. Meaning    Multigene panel testing should be considered for all patients with early-onset colorectal cancer. Read More:   Prevalence and Spectrum of Gene Mutations and Colorectal Cancer

Preventative Measures for Carriers

Reducing the Risk of Colon Cancer Here are some of the preventive steps you and your doctor can take if your genetic test indicates a risk of developing an inherited cancer: Increased Surveillance Colonoscopy every one to two years beginning at age 20-25 or 5-10 years before the earliest age of a diagnosed colorectal cancer in your family, whichever comes first. Colonoscopy annually after age 40. Preventive Surgery If colon cancer (or an advanced precancerous polyp) is diagnosed in a patient with HNPCC , a full, rather than partial, colectomy is recommended. In carefully selected people, for example, those not willing or able to undergo periodic screening, preventive colectomy may be an option based on a positive genetic test result for HNPCC. Preventive Drug Therapies for Colorectal Cancer: Different drugs for the prevention of colorectal cancer are currently being researched for individuals with HNPCC. None of these drugs are currently approved by the FDA for this purpose. Increa...